Kura Oncology is a biopharmaceutical company focused on the development of innovative medicines for the treatment of cancer
The company is committed to advancing its proprietary drug candidates that target specific genetic and epigenetic drivers of cancer progression, utilizing their expertise in precision medicine to address unmet medical needs. Through rigorous research and clinical trials, Kura aims to bring transformative therapies to patients suffering from various types of cancer, including rare and hard-to-treat forms. Their goal is to improve outcomes and quality of life for patients by providing targeted treatments that leverage the unique characteristics of their tumors.
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Shares of United Parcel Service, Inc. (NYSEUPS) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter sales results and issued FY24 sales
Kura Oncology, Inc. shares are trading higher Tuesday after the company reported preliminary clinical data from the first 20 patients its Komet-007 Phase 1 dose-escalation trial. Kura reported that all newly diagnosed patients treated with ziftomenib and 7+3 achieved a complete remission (CR) with full count recovery, for a CR rate of 100% (5/5), including four patients with NPM1-m acute myeloid leukemia (AML) and one patient with KMT2A-r AML.
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index turning lower on Wednesday. The Dow traded down 0.05% to 37,886.62 while the NASDAQ rose 0.59% to 15,517.32. The S&P 500 also rose, gaining, 0.29% to 4,878.52.
Shares of BlackBerry Limited (NYSEBB) fell sharply during Wednesday’s session after the company announced a proposed private offering of $160 million of convertible senior notes. BlackBerry shares tumbled 17.2% to $2.9387 on Wednesday.
